Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
Natasha B. Leighl, Matthew David Hellmann, Rina Hui et al. · The Lancet Respiratory Medicine · 2019
Cited by 174 works. doi:10.1016/s2213-2600(18)30500-9
Authors
- Natasha B. Leighl
- Matthew David Hellmann
- Rina Hui
- Enric Carcereny
- Enriqueta Felip
- Myung‐Ju Ahn
- Joseph P. Eder
- Ani Sarkis Balmanoukian
- Charu Aggarwal
- Leora Horn
- Amita Patnaik
- Matthew A. Gubens
- Suresh S. Ramalingam
- Gregory M. Lubiniecki
- Jin Zhang
- Bilal Piperdi
- Edward B. Garon
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- SEER Cancer Statistics Review, 1975-2003
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater